Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

Journal of Clinical Oncology - United States
doi 10.1200/jco.2009.22.6480
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Successful Treatment With Sorafenib for Sunitinib-Refractory Metastatic Papillary Renal Cell Carcinoma: Potential Impact of Raf Overexpression on Predicting the Efficacy of Sorafenib

IJU Case Reports
2018English

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Clinical Genitourinary Cancer
OncologyUrology
2014English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

Journal of Clinical Pharmacology
Pharmacology
2009English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Genetic Polymorphisms Associated With a Prolonged Progression-Free Survival in Patients With Metastatic Renal Cell Cancer Treated With Sunitinib

Clinical Cancer Research
Cancer ResearchOncology
2010English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs
OncologyPharmacology
2011English

Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy